203 related articles for article (PubMed ID: 31182782)
1. The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia.
Angenendt L; Bormann E; Pabst C; Alla V; Görlich D; Braun L; Dohlich K; Schwöppe C; Bohlander SK; Arteaga MF; Wethmar K; Hartmann W; Angenendt A; Kessler T; Mesters RM; Stelljes M; Rothenberg-Thurley M; Spiekermann K; Hébert J; Sauvageau G; Valk PJM; Löwenberg B; Serve H; Müller-Tidow C; Lenz G; Wörmann BJ; Sauerland MC; Hiddemann W; Berdel WE; Krug U; Metzeler KH; Mikesch JH; Herold T; Schliemann C
Leukemia; 2019 Dec; 33(12):2830-2841. PubMed ID: 31182782
[TBL] [Abstract][Full Text] [Related]
2. CGRP Signaling via CALCRL Increases Chemotherapy Resistance and Stem Cell Properties in Acute Myeloid Leukemia.
Gluexam T; Grandits AM; Schlerka A; Nguyen CH; Etzler J; Finkes T; Fuchs M; Scheid C; Heller G; Hackl H; Harrer N; Sill H; Koller E; Stoiber D; Sommergruber W; Wieser R
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31756985
[TBL] [Abstract][Full Text] [Related]
3. Calcitonin receptor-like (CALCRL) is a marker of stemness and an independent predictor of outcome in pediatric AML.
Angenendt L; Wöste M; Mikesch JH; Arteaga MF; Angenendt A; Sandmann S; Berdel WE; Lenz G; Dugas M; Meshinchi S; Schliemann C; Rössig C
Blood Adv; 2021 Nov; 5(21):4413-4421. PubMed ID: 34559198
[TBL] [Abstract][Full Text] [Related]
4. Identification and validation of CALCRL-associated prognostic genes in acute myeloid leukemia.
Huang Z; Zhang H; Xing C; Zhang L; Zhu H; Deng Z; Yin L; Dong E; Wang C; Peng H
Gene; 2022 Jan; 809():146009. PubMed ID: 34655717
[TBL] [Abstract][Full Text] [Related]
5. CALCRL induces resistance to daunorubicin in acute myeloid leukemia cells through upregulation of XRCC5/TYK2/JAK1 pathway.
Tang S; Li S; Shi X; Sheng L; Mu Q; Wang Y; Zhu H; Xu K; Zhou M; Xu Z; Wu A; Ouyang G
Anticancer Drugs; 2024 Feb; 35(2):163-176. PubMed ID: 37948318
[TBL] [Abstract][Full Text] [Related]
6. Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells.
Larrue C; Guiraud N; Mouchel PL; Dubois M; Farge T; Gotanègre M; Bosc C; Saland E; Nicolau-Travers ML; Sabatier M; Serhan N; Sahal A; Boet E; Mouche S; Heydt Q; Aroua N; Stuani L; Kaoma T; Angenendt L; Mikesch JH; Schliemann C; Vergez F; Tamburini J; Récher C; Sarry JE
Nat Commun; 2021 Jan; 12(1):422. PubMed ID: 33462236
[TBL] [Abstract][Full Text] [Related]
7.
Wang R; Li M; Bai Y; Jiao Y; Qi X
J Oncol; 2022; 2022():3024360. PubMed ID: 35342399
[TBL] [Abstract][Full Text] [Related]
8. Identifying a novel 5-gene signature predicting clinical outcomes in acute myeloid leukemia.
Sha K; Lu Y; Zhang P; Pei R; Shi X; Fan Z; Chen L
Clin Transl Oncol; 2021 Mar; 23(3):648-656. PubMed ID: 32776271
[TBL] [Abstract][Full Text] [Related]
9. Reduced protocadherin17 expression in leukemia stem cells: the clinical and biological effect in acute myeloid leukemia.
Xu ZJ; Ma JC; Zhou JD; Wen XM; Yao DM; Zhang W; Ji RB; Wu DH; Tang LJ; Deng ZQ; Qian J; Lin J
J Transl Med; 2019 Mar; 17(1):102. PubMed ID: 30922328
[TBL] [Abstract][Full Text] [Related]
10. High Expression of CPT1A Predicts Adverse Outcomes: A Potential Therapeutic Target for Acute Myeloid Leukemia.
Shi J; Fu H; Jia Z; He K; Fu L; Wang W
EBioMedicine; 2016 Dec; 14():55-64. PubMed ID: 27916548
[TBL] [Abstract][Full Text] [Related]
11. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
[TBL] [Abstract][Full Text] [Related]
12. Gene expression changes contribute to stemness and therapy resistance of relapsed acute myeloid leukemia: roles of SOCS2, CALCRL, MTSS1, and KDM6A.
Grandits AM; Wieser R
Exp Hematol; 2021 Jul; 99():1-11. PubMed ID: 34029637
[TBL] [Abstract][Full Text] [Related]
13. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
[No Abstract] [Full Text] [Related]
14. Expression of the Calcitonin Receptor-like Receptor (CALCRL) in Normal and Neoplastic Tissues.
Wende B; Beyer AL; Ruhnke N; Kaemmerer D; Sänger J; Schulz S; Lupp A
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835377
[TBL] [Abstract][Full Text] [Related]
15. TBC1D16 predicts chemosensitivity and prognosis in adult acute myeloid leukemia (AML) patients.
Liu H; Chen P; Yang YL; Zhu KW; Wang T; Tang L; Liu YL; Cao S; Zhou G; Zeng H; Zhao XL; Zhang W; Chen XP
Eur J Pharmacol; 2021 Mar; 895():173894. PubMed ID: 33476656
[TBL] [Abstract][Full Text] [Related]
16. Low-density lipoprotein receptor (LDLR) is an independent adverse prognostic factor in acute myeloid leukaemia.
Floeth M; Elges S; Gerss J; Schwöppe C; Kessler T; Herold T; Wardelmann E; Berdel WE; Lenz G; Mikesch JH; Hartmann W; Schliemann C; Angenendt L
Br J Haematol; 2021 Feb; 192(3):494-503. PubMed ID: 32511755
[TBL] [Abstract][Full Text] [Related]
17. Focal Adhesion Kinase as a Potential Target in AML and MDS.
Carter BZ; Mak PY; Wang X; Yang H; Garcia-Manero G; Mak DH; Mu H; Ruvolo VR; Qiu Y; Coombes K; Zhang N; Ragon B; Weaver DT; Pachter JA; Kornblau S; Andreeff M
Mol Cancer Ther; 2017 Jun; 16(6):1133-1144. PubMed ID: 28270436
[TBL] [Abstract][Full Text] [Related]
18. Calcitonin Gene-Related Peptide Rescues Proximity Associations of Its Receptor Components, Calcitonin Receptor-Like Receptor and Receptor Activity-Modifying Protein 1, in Rat Uterine Artery Smooth Muscle Cells Exposed to Tumor Necrosis Factor Alpha.
Dong Y; Chauhan M; Belfort M; Yallampalli C
Biol Reprod; 2016 Dec; 95(6):126. PubMed ID: 27784654
[TBL] [Abstract][Full Text] [Related]
19. High expression of miR-363 predicts poor prognosis and guides treatment selection in acute myeloid leukemia.
Zhang H; Zhang N; Wang R; Shao T; Feng Y; Yao Y; Wu Q; Zhu S; Cao J; Zhang H; Li Z; Liu X; Niu M; Xu K
J Transl Med; 2019 Apr; 17(1):106. PubMed ID: 30935386
[TBL] [Abstract][Full Text] [Related]
20. Acid ceramidase is upregulated in AML and represents a novel therapeutic target.
Tan SF; Liu X; Fox TE; Barth BM; Sharma A; Turner SD; Awwad A; Dewey A; Doi K; Spitzer B; Shah MV; Morad SA; Desai D; Amin S; Zhu J; Liao J; Yun J; Kester M; Claxton DF; Wang HG; Cabot MC; Schuchman EH; Levine RL; Feith DJ; Loughran TP
Oncotarget; 2016 Dec; 7(50):83208-83222. PubMed ID: 27825124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
